181 related articles for article (PubMed ID: 9927611)
41. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
42. Interaction effects of 5-azacytidine with topoisomerase II inhibitors on CHO cells, as detected by cytogenetic analysis.
Takahashi-Hyodo SA; Sakamoto-Hojo ET; Takahashi CS
Mutat Res; 1999 Dec; 431(1):13-23. PubMed ID: 10656482
[TBL] [Abstract][Full Text] [Related]
43. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
44. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.
Srivastava RK; Sasaki CY; Hardwick JM; Longo DL
J Exp Med; 1999 Jul; 190(2):253-65. PubMed ID: 10432288
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
46. Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter.
Faris M; Latinis KM; Kempiak SJ; Koretzky GA; Nel A
Mol Cell Biol; 1998 Sep; 18(9):5414-24. PubMed ID: 9710625
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues.
Pastwa E; Ciesielska E; Piestrzeniewicz MK; Denny WA; Gniazdowski M; Szmigiero L
Biochem Pharmacol; 1998 Aug; 56(3):351-9. PubMed ID: 9744573
[TBL] [Abstract][Full Text] [Related]
48. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
49. Induction of fusion-competent myoblast-specific gene expression during myogenic differentiation of Drosophila Schneider cells by DNA double-strand breaks or replication inhibition.
Hossain MS; Kurokawa K; Sekimizu K
Biochim Biophys Acta; 2005 Mar; 1743(1-2):176-86. PubMed ID: 15777853
[TBL] [Abstract][Full Text] [Related]
50. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
51. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
Davies SL; Bergh J; Harris AL; Hickson ID
Br J Cancer; 1997; 75(6):816-21. PubMed ID: 9062401
[TBL] [Abstract][Full Text] [Related]
52. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
[TBL] [Abstract][Full Text] [Related]
53. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.
Jensen PB; Sehested M
Biochem Pharmacol; 1997 Oct; 54(7):755-9. PubMed ID: 9353129
[TBL] [Abstract][Full Text] [Related]
54. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein.
Mo YY; Ameiss KA; Beck WT
Biotechniques; 1998 Dec; 25(6):1052-7. PubMed ID: 9863061
[TBL] [Abstract][Full Text] [Related]
56. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
57. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.
Umemura K; Yanase K; Suzuki M; Okutani K; Yamori T; Andoh T
Biochem Pharmacol; 2003 Aug; 66(3):481-7. PubMed ID: 12907247
[TBL] [Abstract][Full Text] [Related]
59. NF-kappa B-dependent Fas ligand expression.
Hsu SC; Gavrilin MA; Lee HH; Wu CC; Han SH; Lai MZ
Eur J Immunol; 1999 Sep; 29(9):2948-56. PubMed ID: 10508269
[TBL] [Abstract][Full Text] [Related]
60. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
